Fewer than a tenth of people that would benefit from weight-loss injections including Wegovy can access them, states the global health agency as it issues its initial guidance on the medications.
Given over a billion individuals worldwide now classified as obese, it is urging broader and more equitable availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"The new guidance affirms that excess weight is a long-term condition that can be treated with comprehensive and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are significant hurdles to universal access to the jabs that can help people shift substantial body mass, explains the body.
Skinny Jab Scarcity
Despite the present most favorable scenario, the production of these medications would only suffice for around 100 million people – less than 10% of the global need, according to the WHO.
The advice calls on nations and manufacturers to expand availability, by measures such as patent sharing.
The intellectual property rights on the active ingredient – the main component of a leading brand – is scheduled to end in a number of countries in 2026.
How Obesity Jabs Function
GLP-1 drugs replicate a biological compound to delay gastric emptying, curb appetite and increase the sense of being full so people reduce food intake.
Patients usually see weight reduction after several weeks of commencing the regular doses.
Studies suggests users may put most of the weight back on a year later of stopping the drug, because their typical hunger come back.
To be carrying excess weight raises your chance for experiencing diseases, like type 2 diabetes, heart disease, stroke, and specific cancers.
Excess weight impacts people in all nations and was associated with over three and a half million deaths worldwide in 2024, as per the health agency.
